AbbVie’s Ubrogepant Study: A Potential Breakthrough in Menstrual Migraine Treatment

AbbVie has initiated a Phase 3 clinical study to evaluate the efficacy and safety of ubrogepant for the prevention of menstrual migraines. The study aims to assess the safety and effectiveness of ubrogepant in treating menstrual migraine, a condition characterized by migraine attacks around the menstrual period. The study began on September 10, 2024, with a primary completion date projected for 2025. Positive results could expand AbbVie's product portfolio in the migraine treatment market and potentially enhance investor confidence.